Clinical trials: Regorafenib
Advanced Biliary Tract Cancer
Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer
To evaluate the efficacy and safety of Cadonilimab in combination with Regorafenib and Gem-Cis chemotherapy in advanced biliary tract Cancer
- Trial name
- NCT05820906
- Testing
- Cadonilimab+Regorafenib+GC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Solid Tumor
Study of Regorafenib and Sildenafil for Advanced Solid Tumors
This is a phase 1 study of sildenafil in combination with regorafenib in patients with progressive advanced solid tumors. A modified 3+3 dose escalation design will be conducted for the dose escalation of the treatment…
- Trial name
- NCT02466802
- Testing
- Regorafenib, Sildenafil Citrate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Virginia Commonwealth University
Solid Cancer
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03890731
- Testing
- BAY73-4506 (Regorafenib, Stivarga)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 6 people
- Sponsor
- Bayer
Advanced Hepatocellular Carcinoma (HCC)
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of Camrelizumab Combined with Rivoceranib Mesylate versus Investigator's Choice of Regimen in Treatment of…
- Trial name
- NCT04985136
- Testing
- camrelizumab；Rivoceranib, Rivoceranib, Sorafenib
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma Non-resectable
Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
This study is conducted to evaluate the efficacy and safety of regorafenib plus sintilimab compared with regorafenib alone as the second-line treatment for patients with unresectable hepatocellullar carcinoma (HCC).
- Trial name
- REGSIN (NCT04718909)
- Testing
- Regorafenib + sintilimab, Regorafenib
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Neoplasms
BAY73-4506 Probe Substrate Study
To evaluate the effect of BAY73-4506 on the pharmacokinetics of probe substrates of CYP 2C9 (warfarin), 2C19 (omeprazole) and 3A4 (midazolam) administered in a cocktail approach and on the pharmacokinetics of a probe substrate of…
- Trial name
- NCT01287598
- Testing
- Regorafenib (Stivarga, BAY73-4506), Warfarin, Omeprazole
- Where
- 4 sites in Canada
- Volunteers
- 41 people
- Sponsor
- Bayer
Rectal Cancer Patients
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
This study is a multicenter, prospective, randomized, double-arm, Phase II clinical trial designed to evaluate the efficacy of short-term radiotherapy combined with Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as…
- Trial name
- NCT06911684
- Testing
- lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC
To investigate efficacy and toxicity of regorafenib after treatment with atezolizumab and bevacizumab combination
- Trial name
- HCC (NCT05134532)
- Testing
- regorafenib
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- CHA University
Ovarian Cancer, Primary Peritoneal Cancer
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
This will be a non-blinded, single arm study to test the efficacy of Regorafenib in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02278783
- Testing
- regorafenib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Colorectal Cancer
GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
In this single-center,open-label, randomized, phase II study, the efficacy and feasibility of GSL synthetase inhibitor in combination with immune checkpoint inhibitor and/or regorafenib therapeutic regimen will be evaluated in…
- Trial name
- NCT06558773
- Testing
- Regorafenib+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor +Regorafenib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital
Neoplasms
Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
This will be an uncontrolled, open-label, non-randomized, phase I study. The primary objectives of this study are to define the pharmacokinetics (PK) and to evaluate the safety and tolerability of Regorafenib administered orally…
- Trial name
- NCT01096030
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 4 sites in Hong Kong, Singapore
- Volunteers
- 33 people
- Sponsor
- Bayer
Sintilimab, Cetuximab, Regorafenib,Combine,mCRC
Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)
The incidence of colorectal cancer ranks the third in the world and the mortality ranks the second in the world. The incidence and mortality of colorectal cancer have increased in China in the past decade.
- Trial name
- NCT04745130
- Testing
- Sintilimab，regofinib，cetuximab, KRAS BRAF mutant Sintilimab + regafinil
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Neoplasms
Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
To determine the efficacy (as measured by progression-free survival [PFS] rate at 8 weeks) of regorafenib in subjects with metastatic colorectal cancer (CRC) whose disease is refractory to standard therapies and who were never…
- Trial name
- NCT02465502
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Brazil
- Volunteers
- 59 people
- Sponsor
- Bayer
HER2 + Breast Cancer, Advanced Breast Cancer
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer
This study is a single-arm, exploratory clinical trial, aiming to include patients with HER2-positive advanced breast cancer. It intends to explore the efficacy and safety of trastuzumab combined with pyrotinib, capecitabine ±…
- Trial name
- NCT07766772
- Testing
- Trastuzumab Rezetecan, Pyrotinib, trastuzumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Cancer Hospital
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST)
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically…
- Conditions
- Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases
- Trial name
- NCT05489237
- Testing
- IDRX-42
- Where
- 31 sites in United States, Belgium and 9 more
- Volunteers
- 276 people
- Sponsor
- IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Digestive System Cancers
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
The study is an interventional phase II clinical trial aiming to evaluate the efficacy and safety of KN046, a PD-L1 and CTLA-4 bispecific antibody, in combination with regorafenib or apatinib for microsatellite instability-high…
- Trial name
- NCT06099821
- Testing
- KN046, Regorafenib, Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Microsatellite Stable Metastatic Colorectal Cancer
Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
The study compares the efficacy and safety of regorafenib alone or in combination with hypofractionated radiotherapy and low-dose radiotherapy (LDRT) plus toripalimab in patients with microsatellite stable metastatic colorectal…
- Trial name
- SLOT (NCT05963490)
- Testing
- Regorafenib, Toripalimab, Radiotherapy
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma.
- Trial name
- NCT06363006
- Testing
- TKI+Cardunilimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Neoplasm
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Continuous dosing of BAY73-4506 in patients with advanced cancer
- Trial name
- NCT01117623
- Testing
- Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg, Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg
- Where
- 5 sites in United States
- Volunteers
- 86 people
- Sponsor
- Bayer
Colorectal Cancer
Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer
This is an observational, ambispective cohort study. The aim is to compare the efficacy and safety of regorafenib versus fruquintinib conducted in China.
- Trial name
- NCT04431791
- Testing
- Regorafenib, Fruquintinib
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Peking University